|Spark Therapeutics Announces Filing of Registration Statement for Proposed ...|
Spark's validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark builds on ...
GlobeNewswire (press release) - Wed, 25 Nov 2015 14:18
|Spark Therapeutics Receives Average Recommendation of "Buy" from Analysts ...|
The Company's product development portfolio includes product candidates targeting expression of genes in the liver, with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its ...
Dakota Financial News - Thu, 26 Nov 2015 11:52
|TG Therapeutics Stock Price Down 1.6% (TGTX)|
Putnam Standard - Thu, 26 Nov 2015 05:41
|Infinity Pharmaceuticals, Inc. Short Interest Update|
The Companys lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective ...
American Trade Journal - Wed, 25 Nov 2015 05:52
|Infinity Pharmaceuticals Stock Price Up 4.2% (INFI)|
Putnam Standard - Wed, 25 Nov 2015 17:30
|Personalized T-cell therapy yields promising outcomes in relapsed, refractory CLL|
CLL continues to be incurable with traditional therapeutic approaches, and patients with multiply relapsed or refractory disease face poor outcomes. Thus, David L. Porter, MD, Jodi Fisher Horowitz professor in leukemia care excellence and director of ...
Healio - Tue, 24 Nov 2015 23:07
|Updates from Vienna 2015 – Highlights in Hematologic Malignancies|
The management of patients with hematologic malignancies—from diagnosis to treatment decisions—can represent a challenge for hematologists and oncologists due to several factors, including lack of nonspecific/overlapping symptoms, and the rapidly ...
Healio - Fri, 30 Oct 2015 02:50
|Gaining a Fuller Understand of Neurotoxicity From CAR T Cell Therapy|
CAR T-cell therapies have shown complete response rates of more than 90 percent across a variety of early phase studies for patients with hematologic malignancies, although these agents are not without adverse events (AEs). There are currently numerous ...
Curetoday.com - Mon, 23 Nov 2015 14:18
|KaloBios Pharmaceuticals CEO Martin Shkreli Acquires 5000 Shares (KBIO)|
The Company's principal pharmaceutical product candidates include: KB004, KB003 and KB001‑A. KB004 is a Humaneered anti EphA3 monoclonal antibody that has the potential to offer an approach to treating both hematologic malignancies and solid ...
Voice Chronicle - Wed, 25 Nov 2015 13:45
|KaloBios Pharmaceuticals (KBIO) Soars 4000 Percent in Just Six Days|
Opptrends - Mon, 23 Nov 2015 16:00
|Amgen (AMGN) Announces EC Approval of BLINCYTO for Treatment of Adults with ...|
"BLINCYTO has demonstrated efficacy in treating relapsed or refractory ALL, a very difficult-to-treat disease for which historically patients had limited therapeutic options. This approval represents an important milestone in immunotherapy research ...
StreetInsider.com - Mon, 23 Nov 2015 22:56
|European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the ...|
FiercePharma - Tue, 24 Nov 2015 03:37